NCT03001414 - Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

May 4, 2023

Study Completion Date

November 1, 2023

Conditions

Hypertension,Pulmonary

Interventions

BIOLOGICAL

Placebo followed by Autologous EPCs transfected with human eNOS

4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months

BIOLOGICAL

Autologous EPCs transfected with human eNOS followed by Placebo

4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months

BIOLOGICAL

Autologous EPCs transfected with human eNOS

4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months

Trial Locations (4)

Peter Lougheed Center, University of Calgary, Calgary

London Health Sciences Center, London

University of Ottawa Heart Institute, Ottawa

Toronto General Hospital, Toronto